AcelRx Pharmaceuticals Inc. [NASDAQ: ACRX] stock went on an upward path that rose over 6.95% on Tuesday, amounting to a one-week price increase of more than 27.65%. The company report on January 20, 2021 that AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock.
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of approximately $27.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by AcelRx. The offering is expected to close on or about January 22, 2021, subject to customary closing conditions. In addition, AcelRx has granted the underwriter a 30-day option to purchase up to approximately 2.2 million additional shares of common stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
Over the last 12 months, ACRX stock rose by 63.91%. The average equity rating for ACRX stock is currently 2.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $290.74 million, with 113.81 million shares outstanding and 88.85 million shares in the current float. Compared to the average trading volume of 4.89M shares, ACRX stock reached a trading volume of 8118367 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on AcelRx Pharmaceuticals Inc. [ACRX]:
Credit Suisse have made an estimate for AcelRx Pharmaceuticals Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 20, 2020. While these analysts kept the previous recommendation, Credit Suisse dropped their target price from $7 to $2. The new note on the price target was released on November 11, 2019, representing the official price target for AcelRx Pharmaceuticals Inc. stock.
The Average True Range (ATR) for AcelRx Pharmaceuticals Inc. is set at 0.28, with the Price to Sales ratio for ACRX stock in the period of the last 12 months amounting to 55.91.
ACRX Stock Performance Analysis:
AcelRx Pharmaceuticals Inc. [ACRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.65. With this latest performance, ACRX shares gained by 105.19% in over the last four-week period, additionally plugging by 100.72% over the last 6 months – not to mention a rise of 63.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRX stock in for the last two-week period is set at 72.40, with the RSI for the last a single of trading hit 77.28, and the three-weeks RSI is set at 69.27 for AcelRx Pharmaceuticals Inc. [ACRX]. The present Moving Average for the last 50 days of trading for this stock 1.70, while it was recorded at 2.46 for the last single week of trading, and 1.48 for the last 200 days.
Insight into AcelRx Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and AcelRx Pharmaceuticals Inc. [ACRX] shares currently have an operating margin of -2368.06 and a Gross Margin at -197.34. AcelRx Pharmaceuticals Inc.’s Net Margin is presently recorded at -2325.91.
Return on Total Capital for ACRX is now -56.97, given the latest momentum, and Return on Invested Capital for the company is -60.73. Additionally, ACRX Total Debt to Total Capital is recorded at 151.53, with Total Debt to Total Assets ending up at 133.32.
Reflecting on the efficiency of the workforce at the company, AcelRx Pharmaceuticals Inc. [ACRX] managed to generate an average of -$537,778 per employee. Receivables Turnover for the company is 4.58 with a Total Asset Turnover recorded at a value of 0.02.AcelRx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 2.90.
ACRX Stock EPS
With the latest financial reports released by the company, AcelRx Pharmaceuticals Inc. posted -0.18/share EPS, while the average EPS was predicted by analysts to be reported at -0.2/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRX.
AcelRx Pharmaceuticals Inc. [ACRX] Insider Position Details
There are presently around $62 million, or 25.40% of ACRX stock, in the hands of institutional investors. The top three institutional holders of ACRX stocks are: BLACKROCK INC. with ownership of 5,640,946, which is approximately 3.408% of the company’s market cap and around 2.11% of the total institutional ownership; VANGUARD GROUP INC, holding 4,083,918 shares of the stock with an approximate value of $11.31 million in ACRX stocks shares; and ROCK SPRINGS CAPITAL MANAGEMENT LP, currently with $10.45 million in ACRX stock with ownership of nearly New of the company’s market capitalization.
Positions in AcelRx Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 31 institutional holders increased their position in AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] by around 5,755,804 shares. Additionally, 28 investors decreased positions by around 886,785 shares, while 20 investors held positions by with 15,783,763 shares. The mentioned changes placed institutional holdings at 22,426,352 shares, according to the latest SEC report filing. ACRX stock had 7 new institutional investments in for a total of 4,115,681 shares, while 9 institutional investors sold positions of 383,186 shares during the same period.